急性心肌梗死的静脉溶栓治疗  

Intravenous Thrombolysis in Acute Myocardial Infarction

作　　者：杨波[1] 李天德[1] 胡显文[2] 

机构地区：[1]解放军总医院心内科,北京100853 [2]军事医学科学院生物工程研究所,北京100071

出　　处：《生物技术通讯》2005年第1期100-104,共5页Letters in Biotechnology

摘　　要：溶栓是治疗急性心肌梗死最有前途的方法。梗死相关动脉的尽快开通是保护心肌、提高患者生存率的关键。本文旨在概述已得到认可的溶栓剂和相关的临床试验,包括链激酶、尿激酶、重组组织型纤溶酶原激活剂等。辅助治疗如肝素、水蛭素、血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂也在本文综述之列。Fibrinolytic therapy has been the most promising treatment for acute myocardial infarction. Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium and improving survival. This review will focus on approved agents and the clinical trials that have led to their widespread use, including streptokinase, urokinase, recombinant tissue-type plasminogen activator. The adjunctive therapies, such as heprin, hirudin and GPⅡb/Ⅲa inhibitor, also will be discussed.

关 键 词：急性心肌梗死 静脉溶栓治疗 溶栓剂 链激酶 尿激酶 重组组织型纤溶酶原激活剂 辅助治疗 

分 类 号：R542.22[医药卫生—心血管疾病] R973.2[医药卫生—内科学]